Antiviral immune response against HTLV-1 invalidates T-SPOT.TB^® results in patients with HTLV-1-positive rheumatic diseases.

ABSTRACT:

Background

T-SPOT.TB^®, one of the screening tests for latent tuberculosis infection (LTBI), yields invalid results in human T-cell leukemia virus type 1 (HTLV-1)-positive patients with rheumatoid arthritis. However, the detailed mechanisms behind this invalidation are unclear. Additionally, it remains unclear whether T-SPOT.TB^® or QuantiFERON-TB (QFT) is more useful in HTLV-1-positive patients with rheumatic disease (RD).

Method

Among all of the HTLV-1-positive RD patients who visited our department between August 2012 and December 2022, 44 patients who were screened using T-SPOT.TB® were included in the analysis. QFT testing was performed in 33 of the 44 patients, and the results were compared with that of T-SPOT.TB®. Furthermore, we performed a cultur

SUBMITTER: Kimura M 

PROVIDER: S-EPMC11554456 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature